Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 8/20 | 0.57 |
| ▸ | F11 | P03951 | 3/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | MC1R | Q01726 | 1/20 | 0.54 |
| ▸ | PRLHR | P49683 | 2/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374066 | 0.87 | MC4R (0.53) | F12ALBTSLPRXFP1MC4R | |
| SCHEMBL30893931 | 0.84 | F12 (0.55) | F12TSLPMC4RMC3RMC1R | |
| SCHEMBL29462295 | 0.80 | MC4R (0.70) | F12F11RXFP1MC4RMC3R | |
| SCHEMBL15987187 | 0.80 | F12 (0.67) | F12 | |
| SCHEMBL29389059 | 0.78 | KCNMA1 (0.66) | F11TSLPRXFP1PRLHR | |
| SCHEMBL24256559 | 0.78 | MC4R (0.61) | F11RXFP1MC4RMC3RMC1R | |
| SCHEMBL24256618 | 0.78 | MC4R (0.63) | F11MC4RMC3RMC1R | |
| Polyphemusin Ii SCHEMBL29449206 | 0.78 | F12 (0.62) | F12MC4RMC1R | |
| SCHEMBL31017614 | 0.77 | KLKB1 (0.58) | F12EPHA2 | |
| SCHEMBL27179393 | 0.77 | MC4R (0.62) | F11RXFP1MC4RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 826 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | claimed |
| EP-4615519-A2 | TREATMENT OF NEUROLOGICAL DISORDER USING NHR | Ocugen, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-120091835-A | Treatment of neurological disorders using NHR | 奥古根有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-12318393-B2 | Modulators of orphan nuclear receptors for NASH and other metabolic disorders | EMORY UNIVERSITY | 2025-06-03 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| US-12247064-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-03-11 | — | — | US | claimed |
| EP-3878859-B1 | NOVEL OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY COMPRISING THE SAME | HANMI SCIENCE CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| US-20230314412-A1 | Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases | FLORICA THERAPEUTICS INC (US) | 2023-10-05 | — | — | US | claimed |
| US-11667688-B2 | Glucagon derivative and a composition comprising a long acting conjugate of the same | HANMI PHARM. CO., LTD. (KR) | 2023-06-06 | — | — | US | claimed |
| CN-108495929-B | Differentiation induction into hypothalamic neurons by human pluripotent stem cells | 国立大学法人名古屋大学 | 2023-04-18 | — | — | CN | claimed |
| US-11401315-B2 | Immunoglobulins and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-02 | — | — | US | claimed |
| US-20220127325-A1 | GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME | HANMI PHARM. CO., LTD. (KR) | 2022-04-28 | — | — | US | claimed |
| US-11261227-B2 | Glucagon derivative and a composition comprising a long acting conjugate of the same | HANMI PHARM. CO., LTD. (KR) | 2022-03-01 | — | — | US | claimed |
| US-11254724-B2 | Glucagon derivatives | HANMI PHARM. CO., LTD. (KR) | 2022-02-22 | — | — | US | claimed |
| US-20220025012-A1 | GLUCAGON DERIVATIVES | HANMI PHARM IND CO LTD (KR) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247064-B2 | Modified ligand-gated ion channels and methods of use | GRIK4, GRIK2, GRIK5 | F12 4718/4885F11 4632/4885ALB 3806/4885 |
| US-12318393-B2 | Modulators of orphan nuclear receptors for NASH and other metabolic disorders | RORA, RORB, RORC | F12 4860/4885F11 4715/4885ALB 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.